Honeycomb Bio is active in the single cell genomics arena. The technology was originally found and incubated by one of the large strategic acquirors in the space. This is one of the hottest areas in molecular biology now and the Honeycomb product solves a key problem; current technologies only work on fresh tissue samples. When the product is launched it will be enabling to a number of other players and should be an attractive acquisition target. We expect the public company that incubated Honeycomb will want to scoop it up as originally planned, but if not, we are comfortable that others will be interested in investing or acquiring.